For Yohana, the silence from the Colombian judicial system is as deafening as the loss of her daughter, Valery. Six years ago, a medical treatment intended to save a child’s life instead ended it. Valery was one of at least four children who died after receiving a contaminated cancer medication produced by the Indian pharmaceutical company Naprod.
As a physician, I know that the sterility of injectable oncology drugs is non-negotiable. When a medication like methotrexate—used to treat various cancers and autoimmune diseases—is contaminated with bacteria, it transforms a life-saving therapy into a delivery system for sepsis. In Valery’s case, the contamination was not a sudden accident, but the result of a systemic failure in oversight that spanned two continents.
Despite the deaths and the subsequent discovery of bacteria in the vials, the path to accountability has been blocked by regulatory loopholes and bureaucratic inertia. While families in Colombia continue to wait for a court date, Naprod has continued to operate globally, exporting hundreds of thousands of vials to markets across Africa, Asia, and Latin America.
A Warning Ignored
The tragedy was preventable. Throughout 2019, the Colombian regulator, Invima, received more than 70 reports of severe adverse reactions linked to Naprod’s methotrexate in hospitals across the country. The majority of these patients were children.
By January 2020, the alarm had become an emergency. Invima completed an analysis of a sealed sample of the drug, which confirmed the presence of bacteria. Yet, no immediate recall was issued, and no warning was sent to the hospitals administering the drug. One week after this finding, Valery received the injection that would lead to her death.
The regulator only acted after the damage was done. On February 8, 2020, while Valery was already in a coma, Invima ordered the withdrawal of two specific lots of the medication. Less than two weeks later, the agency ordered a total recall of all Naprod methotrexate in the country.
| Period | Event | Regulatory Action |
|---|---|---|
| 2019 | 70+ reports of severe reactions in children | Monitoring only |
| Jan 2020 | Bacteria confirmed in sealed sample | No immediate action |
| Feb 8, 2020 | Valery in coma; bacteria found in 3 lots | Partial lot withdrawal |
| Late Feb 2020 | Four children confirmed dead | Total product recall |
The Global Reach of Substandard Medicine
While the Colombian government struggled to respond, the manufacturer’s business remained largely intact. In India, the deputy commissioner of the regulator, Bhushan Patil, stated that Naprod’s license to manufacture methotrexate was eventually canceled. But, legal experts suggest this was a superficial victory.
Shri Singh, a criminal lawyer specializing in Indian drug laws, describes the license cancellation as a “velvet glove” strike, noting that the company can simply reapply for the license and resume production. This regulatory flexibility allows companies to weather scandals without facing permanent dissolution.
The danger extends far beyond Colombia. Since Valery’s death, Naprod has exported hundreds of thousands of methotrexate vials to countries including Algeria, Cambodia, Chile, Jamaica, the Philippines, Peru, and Thailand. While Patil indicated the company has not manufactured these specific injections in the last two to three years, records show tens of thousands of vials were still exported to Algeria during that same window.
Systemic Gaps in Patient Safety
The ability of a company like Naprod to continue distributing products in Colombia—sending nearly 8 million vials of various medications to the country last year—highlights a critical vulnerability in global pharmacovigilance. Many of these drugs are priced at less than a dollar per vial, making them an irresistible option for resource-strapped health systems.
Angela Caro-Rojas, a pharmacist and former president of the International Society of Pharmacovigilance, emphasizes that the primary role of a regulatory agency is to protect the patient. She notes that Invima has been hampered by resource shortages and personnel cuts, often relying on third-party reports to approve foreign manufacturers rather than conducting independent on-site inspections.
This reliance on “paper audits” creates a blind spot where contaminated batches can enter the supply chain undetected until patients begin dying. The Pan American Health Organization (PAHO) provides support to strengthen these capacities, but for families like Yohana’s, that support arrived too late.
The Search for Legal Closure
In the Colombian courts, the case has reached a stalemate. The Fiscalía General de la Nación has stated that It’s still in the process of gathering evidence, leaving the families in a state of perpetual limbo. For those seeking criminal charges, the legal hurdle of proving direct causality in medical cases can be daunting.
Carolina Gómez, a specialist in regulation and law, describes the delay in Yohana’s case as “unacceptable” and “indignant.” Without a clear admission of fault from Naprod or a definitive ruling on Invima’s negligence, there is no closure—only the continued sale of products from a company that has yet to assume responsibility for the lives lost.
“The time passes and they say nothing,” Yohana says. “It is as if they are not investigating, as if they are not getting to the bottom of what happened.”
Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice.
The next critical checkpoint for the families remains the conclusion of the evidence-gathering phase by the Fiscalía General de la Nación, which will determine if formal charges are filed against the manufacturer or regulatory officials. We will continue to monitor the case as it moves toward the judicial phase.
Do you have experience with medical regulatory failures or insights into pharmaceutical oversight? Share your thoughts in the comments or contact our newsroom.
